<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971291</url>
  </required_header>
  <id_info>
    <org_study_id>AXS-05-TRD-203</org_study_id>
    <nct_id>NCT04971291</nct_id>
  </id_info>
  <brief_title>An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients</brief_title>
  <acronym>TARGET</acronym>
  <official_title>A Randomized, Active-Controlled, Evaluation of AXS-05 for the Treatment of Treatment Resistant Depression in Treatment-Adherent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axsome Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axsome Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in&#xD;
      patients with treatment-resistant major depressive disorder (MDD) who are adherent to study&#xD;
      drug. Subjects are considered to have treatment-resistant MDD if they have had a historical&#xD;
      inadequate response to 1 or 2 prior antidepressant treatments (ADTs) and a prospective&#xD;
      inadequate response to treatment with bupropion SR, during the current major depressive&#xD;
      episode.&#xD;
&#xD;
      The TARGET study will first determine treatment adherence based on analysis of drug&#xD;
      concentrations of dextromethorphan (in the AXS-05 group) and bupropion (in the bupropion&#xD;
      group), and then evaluate the efficacy of AXS-05 in patients determined to be&#xD;
      treatment-adherent. Efficacy data for evaluation of treatment effect will be obtained from&#xD;
      assessments made during study AXS-05-301.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Ã…sberg Depression Rating Scale (MADRS) total score</measure>
    <time_frame>Change from Baseline to Week 6</time_frame>
    <description>The MADRS is used to assess depressive symptomatology during the previous week. Subjects are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>AXS-05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 mg dextromethorphan-105 mg bupropion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion SR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg bupropion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXS-05</intervention_name>
    <description>AXS-05 taken twice daily for 6 weeks</description>
    <arm_group_label>AXS-05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion SR</intervention_name>
    <description>Bupropion taken twice daily for 6 weeks</description>
    <arm_group_label>Bupropion SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Provided written informed consent to participate in Study AXS-05-301&#xD;
&#xD;
          -  Has treatment-resistant depression, defined as an inadequate response to 2 or 3 prior&#xD;
             ADTs&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 40 kg/m2, inclusive&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Suicide risk&#xD;
&#xD;
          -  Treatment with any investigational drug within 6 months&#xD;
&#xD;
          -  History of electroconvulsive therapy (ECT), vagus nerve stimulation, transcranial&#xD;
             magnetic stimulation, or any experimental central nervous system treatment during the&#xD;
             current episode or in the past 6 months&#xD;
&#xD;
          -  Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Axsome Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AXS-05</keyword>
  <keyword>Axsome</keyword>
  <keyword>NMDA receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

